drugset / Trial / NCT00729599

Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.

NCT00729599

Phase 3 Completed 31 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

To prove the safety, in normal conditions, of the Cepacol Teen, a formulation to odontological usage.

Timeline

Start
2008-07
Primary completion
2008-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetylpyridinium Small molecule

Indications

No indication recorded.